Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous
thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists (VKAs) …

FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have
the potential to be both more efficacious and safer than the currently available direct oral …

Patients with end-stage kidney disease (ESKD) experience a high thrombotic risk but are
also at increased risk of bleeding. There is an unmet need for safer antithrombotic therapy in …

Direct oral anticoagulants (DOACs) are currently the first-choice therapy for the prevention of
cardioembolic events in patients with atrial fibrillation and for the treatment of venous …

Pulmonary embolism (PE) is a potentially life-threatening condition requiring prompt
diagnosis and treatment. Recent advances have led to the development of newer …

OBJECTIVES Literature is scarce on the management of patients using direct oral
anticoagulants (DOACs) undergoing elective, urgent and emergency surgery. Therefore, we …

Introduction Falls are the leading cause of injury in older individuals, with intracranial
hemorrhage (ICH) being a common complication. Anticoagulants, such as vitamin K …

Introduction Oral anticoagulation (OAC) significantly mitigates thromboembolism risks in
atrial fibrillation (AF) and venous thromboembolism (VTE) patients yet concern about major …

Compared with the general population, patients with chronic kidney disease (CKD) are more
likely to experience cardiovascular comorbid conditions such as atrial fibrillation (AF). 1 Both …

During the past decade, direct oral anticoagulants (DOACs) have advanced and simplified
the prevention and treatment of venous thromboembolism (VTE). However, there remains a …